Kala Pharmaceuticals Inc
Research Kala Pharmaceuticals Inc (KALA) on Bullrun: market cap USD 5.42M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerKALA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 5.42M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 1.58M
- Free cash flow-USD 1.54M
Valuation Snapshot
latest market cap is USD 5.42M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 26.98M | -USD 32.01M | n/a | -3.31 | USD 7.56M | USD 0 | USD 7.00M |
| FY2024 | USD 0 | -USD 38.51M | -USD 29.59M | n/a | -10.15 | USD 51.18M | USD 30.44M | USD 12.33M |
| FY2023 | USD 0 | -USD 42.20M | -USD 28.54M | n/a | -17.35 | USD 50.90M | USD 34.19M | USD 7.50M |
| FY2022 | USD 3.89M | -USD 44.82M | -USD 79.22M | 34.2% | -29.48 | USD 70.50M | USD 42.94M | USD 18.97M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 5.42M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 15.60M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 42.27M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 18.85M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 60.86M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 79.26M | n/a | n/a | n/a |
About Kala Pharmaceuticals Inc
KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Kala Pharmaceuticals Inc's market cap?
Kala Pharmaceuticals Inc's market capitalization is USD 5.42M.
What does Kala Pharmaceuticals Inc do?
KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent corneal epithelial defects (PCED) research for agentic workflows on trial data.